{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"29.2","upperLimit":"100.0","value":"100.0"},{"groupId":"OG001","lowerLimit":"29.2","upperLimit":"100.0","value":"100.0"},{"groupId":"OG002","lowerLimit":"19.4","upperLimit":"99.4","value":"75.0"},{"groupId":"OG003","lowerLimit":"9.4","upperLimit":"99.2","value":"66.7"},{"groupId":"OG004","lowerLimit":"64.8","upperLimit":"98.1","value":"85.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"13"}],"units":"Participants"}],"description":"ORR is defined as percentage of participants who achieved stringent complete response (sCR), complete response (CR), very good partial response (VGPR) or partial response (PR). International Myeloma Working Group (IMWG) criteria (2011)- CR: Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and less than (\\<) 5 percentage (%) plasma cells in bone marrow; sCR: CR+Normal free light chain ratio and absence of clonal cells in bone marrow by immunohistochemistry or immuno fluorescence; PR: greater than equal to (\\>=) 50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by \\>= 90 percentage (%) or to \\<200 mg/24 hours; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine M-protein level \\<100 mg per 24 hour.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants administered with daratumumab 2 mg/kg on Day 0 (pre dose infusion), 1, 8, 15, 22 (cycle 1), Days 1, 8, 15, and 22 (cycle 2), Days 1 and 15 (Cycles 3 to 6), Day 1 (Cycle 7+) along with Lenalidomide 25 mg on Day 1 to 21 of each 28-day cycle and Dexamethasone 40 mg (weekly) and may be reduced to 20 mg (weekly after cycle 6 at the investigator's discretion). Each treatment cycle consists of 28 days.","id":"OG000","title":"Phase 1: 2 mg/kg Daratumumab + Lenalidomide and Dexamethasone"},{"description":"Participants administered with daratumumab 4 mg/kg on Day 0 (pre dose infusion), 1, 8, 15, 22 (cycle 1), Days 1, 8, 15, and 22 (cycle 2), Days 1 and 15 (Cycles 3 to 6), Day 1 (Cycle 7+) along with Lenalidomide 25 mg on Day 1 to 21 of each 28-day cycle and Dexamethasone 40 mg (weekly) and may be reduced to 20 mg (weekly after cycle 6 at the investigator's discretion). Each treatment cycle consists of 28 days.","id":"OG001","title":"Phase 1: 4 mg/kg Daratumumab + Lenalidomide and Dexamethasone"},{"description":"Participants administered with daratumumab 8 mg/kg on Day 0 (pre dose infusion), 1, 8, 15, 22 (cycle 1), Days 1, 8, 15, and 22 (cycle 2), Days 1 and 15 (Cycles 3 to 6), Day 1 (Cycle 7+) along with Lenalidomide 25 mg on day 1 to 21 of each 28-day cycle and Dexamethasone 40 mg (weekly) and may be reduced to 20 mg (weekly after cycle 6 at the investigator's discretion). Each treatment cycle consists of 28 days.","id":"OG002","title":"Phase 1: 8 mg/kg Daratumumab + Lenalidomide and Dexamethasone"},{"description":"Participants administered with daratumumab 16 mg/kg on Day 0 (pre dose infusion), 1, 8, 15, 22 (cycle 1), Days 1, 8, 15, and 22 (cycle 2), Days 1 and 15 (Cycles 3 to 6), Day 1 (Cycle 7+) along with Lenalidomide 25 mg on Day 1 to 21 of each 28-day cycle and Dexamethasone 40 mg (weekly) and may be reduced to 20 mg (weekly after cycle 6 at the investigator's discretion). Each treatment cycle consists of 28 days.","id":"OG003","title":"Phase 1: 16 mg/kg Daratumumab + Lenalidomide and Dexamethasone"},{"description":"Participants were administered Daratumumab at escalating doses of 2 mg/kg, 4 mg/kg, 8 mg/kg, or 16 mg/kg on Day 0 (pre dose infusion), 1, 8, 15, 22 (cycle 1), Days 1, 8, 15, and 22 (cycle 2), Day 1 of Cycles 3 to 6, and Day 1 of Cycles 7 and beyond. Each cycle consisted of 28 days. Lenalidomide (25 mg was administered orally once daily on Days 1 to 21 of each 28-day cycle) and Dexamethasone (40 mg weekly) were administered concurrently. Dexamethasone dosage could be reduced to 20 mg weekly after Cycle 6 or at the investigator's discretion. Each treatment cycle consisted of 28 days.","id":"OG004","title":"Phase 1: Daratumumab (2-16 mg/kg) + Lenalidomide and Dexamethasone"}],"paramType":"NUMBER","populationDescription":"All treated analysis set included all enrolled participants who received at least one non-zero dose of any study drug during Phase 1.","reportingStatus":"POSTED","timeFrame":"Up to 3 years","title":"Phase 1: Percentage of Participants With Overall Response Rate (ORR)","type":"PRIMARY","unitOfMeasure":"Percentage of participants"}